Sensorion Announces Confidential Submission of Draft Registration Statement to the SEC for Potential U.S. Initial Public Offering

MONTPELLIER, France & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) (“the Company”) a pioneering clinical-stage biotechnology company focused on developing novel therapies to restore hearing and treat and prevent hearing loss disorders, announced today that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (the “SEC”). The confidential submission is a preliminary step in the Company’s